Time: 2024-07-30
The Food and Drug Administration recently approved a new screening test for Colorectal cancer , known as Shield , developed by Guardant Health . Unlike traditional methods like colonoscopies or fecal sample tests , this Blood test offers a more convenient and less invasive option for detecting early - stage cancers that are often treatable.
While Shield may not be as effective at identifying precancerous growths as other screening tests , its approval marks a significant step in encouraging more individuals aged 45 and over , who are at average risk for colon cancer , to undergo regular screenings . This is crucial as colorectal cancer is the second - most common cause of cancer - related deaths in the United States , with an estimated 53,000 deaths expected this year alone.
The availability of Shield will provide individuals with an additional tool to detect colon cancer early , potentially increasing the overall screening rates and ultimately saving lives . Despite its limitations , the convenience and accessibility of a simple blood test may help bridge the gap for those who are hesitant to undergo more invasive procedures like colonoscopies.
Many experts believe that the approval of Shield could help address the issue of under - screening for colon cancer in the United States . Data from the Centers for Disease Control and Prevention reveal that a significant number of eligible adults do not receive timely colonoscopies , and one in five individuals never undergo any form of screening for colon cancer.
By offering an alternative screening method that is easier to access , the hope is to close the gap in screening rates and improve early detection of colon cancer cases . While Shield may not replace traditional methods entirely , it serves as a valuable addition to the toolkit for fighting colorectal cancer and reducing the overall burden of the disease.
Business
